Newsfiscal.ai
Seres Therapeutics Reports Third Quarter 2026 Financial Results and Updates SER-155 Development Plans
· Published
Article summary
Seres Therapeutics reported its third quarter 2026 financial results and announced plans to advance the development of SER-155 for the prevention of immune checkpoint inhibitor-related enterocolitis (irEC).
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…